A renowned Israeli TV journalist who lost his ability to speak clearly because of ALS is returning to the air using ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...

The voice of Israeli journalist Moshe Nussbaum has been revived using artificial intelligence after he was diagnosed with ALS ...

However, as it became increasingly difficult for Nussbaum to speak, and to be understood, his interviews became less frequent ...

A research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other neurodegenerative disorders such as ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing ...

When a renowned Israeli TV journalist lost his ability to speak clearly because of ALS, he thought his career might be over.

A University of California, Irvine-led research team has discovered intricate molecular mechanisms driving the RNA processing defects that lead to Huntington's disease and link HD with other ...

Backed by ARCH Venture Partners, F-Prime Capital and Mubadala Capital, the new company will develop a pipeline of ...